Novo Nordisk (home to Ozempic) released results this morning have left the shares wallowing – 9.5% which now takes the shares down by -41% over the past 6 months. Those are the sort of numbers that only the Ozempic taking customers would be proud of if they applied to their waistlines. The writing has been on the wall.
The Apollo investment cycle (top image) shows the changes in the cycle over time, The shares have been and remain in a Value cycle, not a Growth or Re-rating cycle. The Apollo Investment factors are fluid so that the cycle changes depending on the discount rate / Implied cost of capital the market imposes on the expected returns.
The lower image shows the impact of change. The shares have been de-rating in real time – over time. Knowing what the market knows is essential. Being contrarian or blind to change is inexcusable. The charts below (and 8000 stocks besides) are available on the Apollo EDGE platform.
